Article
Urology & Nephrology
Tarik Benidir, Ethan Austhof, Ryan D. D. Ward, Justin Ream, Jenifer Bullen, Baris Turkbey, Peter A. A. Pinto, Francesco Giganti, Eric A. A. Klein, Andrei S. S. Purysko
Summary: The study aimed to evaluate the impact of UroLift on prostate magnetic resonance imaging (MRI) quality. The results showed that UroLift has a negative impact on MRI quality, particularly in the mid-basal region, obscuring a significant portion of the prostate on diffusion-weighted images.
JOURNAL OF UROLOGY
(2023)
Review
Urology & Nephrology
Bernardo Rocco, Ahmed Eissa, Giorgia Gaia, Simone Assumma, Luca Sarchi, Giorgio Bozzini, Salvatore Micali, Tommaso Calcagnile, Maria C. Sighinolfi
Summary: Prostate cancer and bladder cancer are significant contributors to male cancers and newly diagnosed cancers, causing a substantial health and economic burden worldwide. Understanding lymph node status is crucial in managing solid tumors, with pelvic lymph node dissection (pLND) being a vital part of the diagnosis, management, and prognosis of prostate and bladder cancers. However, pLND may have associated complications. This review discusses the latest updates on lymph node metastasis patterns and incidence, the role of different imaging studies and nomograms in determining pLND eligibility, and anatomical templates for pLND in urologic patients with bladder or prostate cancer.
MINERVA UROLOGY AND NEPHROLOGY
(2022)
Article
Urology & Nephrology
Ahmet Urkmez, Cihan Demirel, Muammer Altok, Tharakeswara K. Bathala, Daniel D. Shapiro, John W. Davis
Summary: Compared with the GB method, the FH technique of transperineal prostate biopsy has equivalent cancer yield, reduced risk of urinary retention, and lower anesthesia needs. The FH method may sample the prostate better given the higher number of cores with >= GGG-2 PCa involvement.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Zoila A. Lopez-Bujanda, Aleksandar Obradovic, Thomas R. Nirschl, Laura Crowley, Rodney Macedo, Alexandros Papachristodoulou, Timothy O'Donnell, Uri Laserson, Jelani C. Zarif, Ran Reshef, Tiezheng Yuan, Mithil K. Soni, Emmanuel S. Antonarakis, Michael C. Haffner, H. Benjamin Larman, Michael M. Shen, Pawel Muranski, Charles G. Drake
Summary: This study identified a set of androgen-responsive genes as potential tumor-associated antigens for prostate cancer. Transglutaminase 4 (Tgm4) was found to be highly expressed in prostate tumors from luminal epithelial cells and had low expression in most non-prostate tissues. TGM4's immunogenicity was confirmed, suggesting its potential as an immunotherapy target for prostate cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Health Care Sciences & Services
Archana Radhakrishnan, Lauren P. Wallner, Ted A. Skolarus, Paul H. Abrahamse, Adam S. Kollipara, Steven J. Katz, Sarah T. Hawley
Summary: The majority of PCPs were confident in engaging with patients in low-risk prostate cancer treatment decision-making, but their intended participation varied widely across four key aspects of active surveillance care.
JOURNAL OF GENERAL INTERNAL MEDICINE
(2021)
Article
Oncology
Anna Sofia Trigos, Anupama Pasam, Patricia Banks, Roslyn Wallace, Christina Guo, Simon Keam, Heather Thorne, Catherine Mitchell, Stephen Lade, David Clouston, Alexander Hakansson, Yang Liu, Benjamin Blyth, Declan Murphy, Nathan Lawrentschuk, Damien Bolton, Daniel Moon, Phil Darcy, Ygal Haupt, Scott G. Williams, Elena Castro, David Olmos, David Goode, Paul Neeson, Shahneen Sandhu
Summary: Aberrations in homologous recombination repair genes are important biomarkers for personalized treatment in prostate cancer. Tumors with homologous recombination repair deficiency may affect the tumor immune microenvironment, potentially leading to differential responses to PARP inhibitors and immune checkpoint inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Cedric Draulans, Robin De Roover, Uulke A. van der Heide, Linda Kerkmeijer, Robert J. Smeenk, Floris Pos, Wouter V. Vogel, James Nagarajah, Marcel Janssen, Sofie Isebaert, Frederik Maes, Cindy Mai, Raymond Oyen, Steven Joniau, Martina Kunze-Busch, Karolien Goffin, Karin Haustermans
Summary: Threshold-based contouring using SOSTs trained with GTV(majority) achieved accuracy comparable to manual contours in delineating GTV(histo). Median SOSTs were found to be 41 SUV% for 68Ga-PSMA-11 PET and 44 SUV% for 18F-PSMA-1007 PET, forming a basis for tracer-specific window leveling.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Article
Endocrinology & Metabolism
Busra Ozbek, Onur Ertunc, Andrew Erickson, Igor D. Vidal, Carolina Gomes-Alexandre, Gunes Guner, Jessica L. Hicks, Tracy Jones, Janis M. Taube, Karen S. Sfanos, Srinivasan Yegnasubramanian, Angelo M. De Marzo
Summary: This study aims to develop a chromogenic-based multiplex immunohistochemistry method to quantify T cell subsets in the tumor microenvironment of primary prostatic adenocarcinomas. The results show that CD4+ T cells are present at higher density than CD8+ T cells, all T cell subsets are present at higher densities in the stromal compartment compared to the epithelial tumor compartment, most CD4+ and CD8+ T cells are PD1+, cancer foci with PTEN loss harbored increased numbers of T cells compared to regions without PTEN loss, in both stromal and epithelial compartments, and the increases in T cells in PTEN loss regions were associated with ERG gene fusion status.
Article
Urology & Nephrology
William T. Lowrance, Rodney H. Breau, Roger Chou, Brian F. Chapin, Tony Crispino, Robert Dreicer, David F. Jarrard, Adam S. Kibel, Todd M. Morgan, Alicia K. Morgans, William K. Oh, Matthew J. Resnick, Anthony L. Zietman, Michael S. Cookson
Summary: This summary focuses on Part I of the series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline, providing prognostic and treatment recommendations for patients with advanced prostate cancer. The guideline includes evidence- and consensus-based statements to improve patient care, with the need for continued research to enhance treatment outcomes in the future.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
James S. Wysock, Eli Rapoport, Hunter Hernandez, Rozalba Gogaj, Herbert Lepor
Summary: This study evaluated the effectiveness of primary partial gland cryoablation in treating localized prostate cancer after 3 years. The results showed successful ablation of localized cancers, but also highlighted the need for long-term surveillance and identification of predictors of clinically significant prostate cancer recurrences.
JOURNAL OF UROLOGY
(2023)
Review
Urology & Nephrology
N. Shore, L. Oliver, I. Shui, A. Gayle, O. Y. Wong, J. Kim, S. Payne, S. Amin, S. Ghate
Summary: This study characterized the global epidemiology of different types of metastatic prostate cancer and assessed the prevalence and prognostic impact of homologous recombination repair gene alterations in advanced disease setting. The results indicated that there is limited real-world evidence on the prevalence of prostate cancer and HRRm beyond mCRPC, with BRCA2 being one of the most common genes associated with HRRm in mCRPC.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
K. Stinesen Kollberg, E. Holmberg, A. Josefsson, J. Hugosson, R. Arnsrud Godtman
Summary: The aim of this study was to describe the level of pre-testing and contamination in the Goteborg-1 prostate cancer screening trial. The results showed that similar proportions of men were prostate specific antigen-tested in both the screening group and control group, yet only a minority of contamination prostate specific antigens led to biopsy. Organized screening was found to be more effective in reducing prostate cancer mortality than non-organized testing.
JOURNAL OF UROLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per S. Sorensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine K. Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander
Summary: This study aimed to compare the cardiovascular safety of GnRH antagonists and agonists in men with prostate cancer, but was terminated prematurely due to slower-than-expected enrollment. No significant difference in major adverse cardiovascular events was observed between patients assigned to GnRH antagonist degarelix and GnRH agonist leuprolide. The relative cardiovascular safety of GnRH antagonists and agonists remains unresolved.
Review
Medicine, General & Internal
Lorenzo Cereser, Laura Evangelista, Gianluca Giannarini, Rossano Girometti
Summary: In recent years, prostate magnetic resonance imaging (MRI) has become essential in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can prevent unnecessary biopsies, a positive examination prompts targeted biopsy samples, leading to increased csPCa diagnosis with high sensitivity and negative predictive value. The limitations of MRI have sparked discussions on how to stratify biopsy decisions and management based on patient risk and accurately estimate it with clinical and/or imaging findings. Next-generation imaging techniques such as radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) are expanding their indications in primary staging and diagnosis, offering increased sensitivity and serving as problem-solving tools in indeterminate MRI cases. This review summarizes the current evidence on the role of prostate MRI and PSMA-PET in the primary diagnosis of csPCa and their potential interactions.
Article
Urology & Nephrology
Clement Orczyk, Dean Barratt, Chris Brew-Graves, Yi Peng Hu, Alex Freeman, Neil McCartan, Ingrid Potyka, Navin Ramachandran, Rachael Rodell, Norman R. Williams, Mark Emberton, Hashim U. Ahmed
Summary: The study found that early efficacy of bipolar radiofrequency ablation with a coil design for focal ablation of clinically significant localized prostate cancer visible at multiparametric magnetic resonance imaging showed low rates of genitourinary and rectal side effects.
JOURNAL OF UROLOGY
(2021)